Aura Biosciences Appoints New Director, Boosts Board Compensation

summarizeSummary

Aura Biosciences appointed Jeremy Bender, Ph.D., M.B.A., to its Board of Directors and significantly increased non-employee director compensation, including larger equity awards, which will contribute to future share dilution.

check_boxKey Events · Executive and Board Changes · AURA

• New Director Appointed

  Jeremy Bender, Ph.D., M.B.A., was appointed as a Class II director, effective July 7, 2026. Dr. Bender brings deep experience in advancing innovative therapies through late-stage development and commercialization in rare oncology.

• Director Compensation Policy Amended

  The company's non-employee director compensation policy was amended on June 11, 2026, significantly increasing both cash retainers and equity awards for new and continuing directors.

• Increased Equity Awards

  Initial equity awards for new directors now include 60,000 stock options (up from 34,000) and 30,000 restricted stock units (up from 26,000), with an aggregate value cap of $800,000. Annual awards for continuing directors also saw similar increases.

auto_awesomeAnalysis · AURA · Life Sciences

This filing details the appointment of Jeremy Bender, Ph.D., M.B.A., to Aura Biosciences' Board of Directors, bringing significant experience in late-stage biotechnology development and commercialization. More notably, the company has amended its non-employee director compensation policy, substantially increasing both cash retainers and equity awards (stock options and restricted stock units). This policy update, which includes an initial equity award cap of $800,000 for new directors, indicates a higher rate of future share dilution for director compensation, following a recent proxy filing seeking approval for a massive increase in authorized shares.